A refined estimate of the average lifetime cost of pelvic inflammatory disease

被引:70
作者
Yeh, JM
Hook, EW
Goldie, SJ
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Harvard Ctr Risk Anal, Boston, MA 02115 USA
[2] Univ Alabama, Birmingham, AL USA
关键词
D O I
10.1097/00007435-200305000-00001
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The major complications of pelvic inflammatory disease (infertility, ectopic pregnancy, and chronic pelvic pain) are the leading cause of non-HIV sexually transmitted disease morbidity in the United States. Goal. The goal of the study was to estimate a plausible range for the average lifetime cost of pelvic inflammatory disease (PID) and its major complications in a cohort of U.S. women of reproductive age. Study Design: We developed a state-transition computer-based model to simulate the natural history of PID, incorporating the severity of infection, number of recurrent episodes, treatment setting, and the risk over time of major complications. Clinical and cost data were from the published literature. Model outcomes included life expectancy, quality-adjusted life expectancy, and lifetime costs. Results: In a cohort of 100,000 females acquiring PID between 20 and 24 years of age, 8550 ectopic pregnancies, 16,800 cases of infertility, and 18,600 cases of chronic pelvic pain were projected to occur. Assuming a 3% annual discount rate, we found the average per-person lifetime cost to be $2150. Average lifetime costs for women who developed major complications were $6350 for chronic pelvic pain, $6840 for ectopic pregnancy, and $1270 for infertility. The majority of costs (79%) were accrued within 5 years of upper genital tract infection. Results were most sensitive to assumptions about the timing of major complications and the discount rate. Conclusion: The average per-person lifetime cost of PID ranges between $1060 and $3180. Future cost-effectiveness analyses of STD screening programs can include this range as a reasonable upper and lower bound. These findings suggest successful PID prevention efforts may avert substantial costs for care providers such as managed care organizations while providing well documented clinical benefits for women in the United States.
引用
收藏
页码:369 / 378
页数:10
相关论文
共 71 条
[51]   EPIDEMIOLOGY OF SEXUALLY-TRANSMITTED CHLAMYDIA-TRACHOMATIS INFECTIONS [J].
THOMPSON, SE ;
WASHINGTON, AE .
EPIDEMIOLOGIC REVIEWS, 1983, 5 :96-123
[52]  
TRACHTENBERG AI, 1988, OBSTET GYNECOL, V71, P101
[53]  
*US BUR LAB STAT, 2000, CONS PRIC IND
[54]   Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens [J].
van Valkengoed, IGM ;
Postma, MJ ;
Morré, SA ;
van den Brule, AJC ;
Meijer, CJLM ;
Bouter, LM ;
Boeke, AJP .
SEXUALLY TRANSMITTED INFECTIONS, 2001, 77 (04) :276-282
[55]   COST OF AND PAYMENT SOURCE FOR PELVIC INFLAMMATORY DISEASE - TRENDS AND PROJECTIONS, 1983 THROUGH 2000 [J].
WASHINGTON, AE ;
KATZ, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (18) :2565-2569
[56]   THE ECONOMIC COST OF PELVIC INFLAMMATORY DISEASE [J].
WASHINGTON, AE ;
ARNO, PS ;
BROOKS, MA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 255 (13) :1735-1738
[57]   PELVIC INFLAMMATORY DISEASE AND ITS SEQUELAE IN ADOLESCENTS [J].
WASHINGTON, AE ;
SWEET, RL ;
SHAFER, MAB .
JOURNAL OF ADOLESCENT HEALTH, 1985, 6 (04) :298-310
[58]   Cost-effectiveness of screening programs for Chlamydia trachomatis -: A population-based dynamic approach [J].
Welte, R ;
Kretzschmar, M ;
Leidl, R ;
Van den Hoek, A ;
Jager, JC ;
Postma, MJ .
SEXUALLY TRANSMITTED DISEASES, 2000, 27 (09) :518-529
[59]   GYNECOLOGICAL CHLAMYDIAL INFECTIONS [J].
WESTROM, L .
INFECTION, 1982, 10 :S40-S45
[60]   INCIDENCE, TRENDS, AND RISKS OF ECTOPIC PREGNANCY IN A POPULATION OF WOMEN [J].
WESTROM, L ;
BENGTSSON, LP ;
MARDH, PA .
BRITISH MEDICAL JOURNAL, 1981, 282 (6257) :15-18